Medication info
Supria Tablet 40/10 mg

Supria Tablet 40/10 mg

Prescription medicationOral
Ingredient · strength
Telmisartan›40mg / 1 tabletAmlodipine Besylate›13.87mg / 1 tablet
Manufacturer / importer
Daehwa Pharmaceutical Co., Ltd.
Appearance
Biconvex oval double-coated tablets in white and light blue
Packaging
30 tablets (10 tablets/PTPX3)
Approval status
Active

MFDS item code 201706344 · Approved 2017.07.31 · Insurance code 645604900

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
The recommended dose is 1 tablet once daily, taken with water, with or without food. If possible, it is recommended that the medicine be taken at the same time every day (e.g., in the morning). It is recommended that the dose be adjusted using the individual components (telmisartan or amlodipine) before starting this medicine; however, direct switching to this medicine may be considered when blood pressure is not adequately controlled with the individual components, as follows: - 40/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this medicine 40/5 milligrams. - 40/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 milligrams in patients with mild or moderate hepatic impairment. ◦ Older adults: The usual amlodipine regimen is recommended for older adults, but caution should be exercised when increasing the dose. (See section “3. Patients Requiring Caution”) In older adults aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually.
Child dose
Use of this medicine is not recommended in pediatric patients 18 years of age or younger because its safety and efficacy have not been established.

Ingredients

Manufacturer
Daehwa Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication effectively helps patients with essential hypertension who have difficulty controlling blood pressure with either telmisartan or amlodipine monotherapy. In such cases, combining the two medications can lead to more stable blood pressure management. This contributes to preventing cardiovascular complications and improving the patient's health status. Therefore, it is used appropriately for blood pressure regulation in essential hypertension.

How to take

Adult dose

The recommended dose is 1 tablet once daily, taken with water, with or without food. If possible, it is recommended that the medicine be taken at the same time every day (e.g., in the morning). It is recommended that the dose be adjusted using the individual components (telmisartan or amlodipine) before starting this medicine; however, direct switching to this medicine may be considered when blood pressure is not adequately controlled with the individual components, as follows: - 40/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this medicine 40/5 milligrams. - 40/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 milligrams in patients with mild or moderate hepatic impairment. ◦ Older adults: The usual amlodipine regimen is recommended for older adults, but caution should be exercised when increasing the dose. (See section “3. Patients Requiring Caution”) In older adults aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually.

Child dose

Use of this medicine is not recommended in pediatric patients 18 years of age or younger because its safety and efficacy have not been established.

Precautions

This medication can cause severe damage to the fetus if taken during pregnancy, particularly in the second and third trimesters, so it should not be used by pregnant women or those who may become pregnant. It is contraindicated in patients with certain conditions, such as severe hepatic impairment, severe hypotension, cardiogenic shock, and unstable heart failure following acute myocardial infarction. Particular caution is required when administering this medication to patients with impaired liver or kidney function, specific valvular heart diseases, or the elderly. During treatment, side effects such as dizziness or peripheral edema may commonly occur, and severe side effects can rare occur; therefore, patients should consult a doctor immediately if unusual symptoms arise. Regular monitoring of blood pressure, kidney function, and serum electrolyte levels is necessary, especially as there is a risk of hyperkalemia, requiring careful observation of potassium levels. Interactions may occur when taken with other antihypertensive medications or specific medicines, so patients should inform their doctor or pharmacist about any other medications they are taking. This medication is not recommended for breastfeeding women and should be avoided during lactation. Safety and efficacy have not been established for children, so its use is not advised. In the case of overdose, hypotension, dizziness, and heart-related problems may occur, so it is important to avoid exceeding the prescribed dose, and seek medical attention immediately if side effects are suspected. Store this medication out of reach of children, do not transfer to another container, and open the packaging just before taking.

Side effects

  • Dizziness
  • peripheral edema
  • syncope
  • upper respiratory infection
  • urinary tract infection
  • cystitis
  • sepsis
  • anemia
  • thrombocytopenia
  • eosinophilia
Show 106 more
  • leukopenia
  • hypersensitivity
  • anaphylactic reaction
  • hyperkalemia
  • hypoglycemia
  • hyponatremia
  • hyperglycemia
  • depression
  • insomnia
  • mood changes
  • anxiety
  • confusion
  • drowsiness
  • headache
  • sensory disturbance
  • sensory loss
  • taste disturbance
  • tremor
  • extrapyramidal disorder
  • muscle rigidity
  • visual impairment
  • vertigo
  • tinnitus
  • palpitations
  • bradycardia
  • tachycardia
  • myocardial infarction
  • ventricular tachycardia
  • arrhythmia
  • atrial fibrillation
  • flushing
  • hypotension
  • orthostatic hypotension
  • vasculitis
  • cough
  • dyspnea
  • rhinitis
  • changes in bowel habits
  • abdominal pain
  • dyspepsia
  • nausea
  • gastrointestinal air retention
  • vomiting
  • dry mouth
  • gum hypertrophy
  • pancreatitis
  • gastritis
  • liver dysfunction
  • hepatic disorder
  • hepatitis
  • jaundice
  • increased liver enzymes
  • pruritus
  • hyperhidrosis
  • rash
  • hair loss
  • purpura
  • skin discoloration
  • eczema
  • erythema
  • angioedema
  • toxic skin rash
  • drug rash
  • urticaria
  • polymorphic erythema
  • exfoliative dermatitis
  • Stevens-Johnson syndrome
  • photosensitivity reaction
  • joint swelling
  • muscle cramps
  • arthralgia
  • myalgia
  • low back pain
  • limb pain
  • tendon pain
  • renal dysfunction
  • urinary disorders
  • frequent urination
  • nocturia
  • erectile dysfunction
  • gynecomastia
  • edema
  • asthenia
  • fatigue
  • chest pain
  • malaise
  • influenza-like illness
  • increased liver enzymes
  • increased blood creatinine
  • weight gain
  • weight loss
  • increased blood uric acid
  • increased blood creatine phosphokinase
  • decreased hemoglobin
  • interstitial lung disease
  • interstitial pneumonia
  • eosinophilic pneumonia
  • hepatic cell carcinoma
  • cerebral infarction
  • congestive heart failure
  • musculoskeletal pain
  • neck pain
  • nasopharyngitis
  • upper abdominal discomfort
  • upper abdominal pain
  • position-related dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that blocks light. Additionally, it should be kept at a normal room temperature between 1°C and 30°C, avoiding extreme heat or cold.

Appearance and packaging

Appearance

Biconvex oval double-coated tablets in white and light blue

Package unit

30 tablets (10 tablets/PTPX3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.